#USA #Drug Discovery #Billerica #Momentum Biotechnologies #OmicScouts

Momentum Biotechnologies Expands Through Acquisition of OmicScouts

BILLERICA, Mass. and MUNICH, March 5, 2025 — Momentum Biotechnologies, a contract research organization (CRO) that specializes in mass spectrometry-based drug discovery, has announced the successful acquisition of OmicScouts GmbH. This move marks a significant expansion for Momentum, as OmicScouts is recognized as a leader in mass spectrometry-based proteomics in Europe.

By acquiring OmicScouts, Momentum enhances its portfolio of services, bringing on board a range of validated proteomic assays. These additions allow clients to transition effortlessly from high-throughput screening to cell-based assays, facilitating the discovery of new biomarkers and therapeutic targets. This acquisition also signals a strategic expansion into the European market, which aligns with Momentum's commitment to delivering top-tier scientific services to biopharmaceutical innovators worldwide.

Dr. Can Ozbal, founder and CEO of Momentum Biotechnologies, expressed the company's enthusiasm about this acquisition, stating, "Our clients have long sought assistance in triaging and further examining the promising leads we identify through high-throughput screens. OmicScouts’ capabilities in chemoproteomics allow us to advance projects beyond mere hit identification to also explore target engagement and specificity, effectively bridging the gap between biochemical screening and subsequent cell-based assays."

Hannes Hahne, Ph.D., co-founder and CEO of OmicScouts, will transition to the role of President and join Momentum's global executive leadership team. Hahne shared, "We founded OmicScouts with the goal of providing researchers with the essential tools and talent for successful proteomics-based drug discovery. The Momentum team shares this vision. Together, we aspire to revolutionize drug discovery by integrating mass spectrometry with various screening methodologies."

The cultural and strategic alignment between OmicScouts and Momentum is underscored by their shared technical foundations and established client relationships. Peter Batesko, Lead Director of Momentum and CEO of Care Equity, the investment firm supporting Momentum, highlighted, "OmicScouts and Momentum are both recognized for their technical excellence and the high trust placed in them by clients. This merger will allow us to couple OmicScouts’ proteomics expertise with our screening technologies, expediting the drug design process for our customers."

Additionally, two of OmicScouts' co-founders and scientific advisers, Dr. Mathias Wilhelm and Dr. Bernhard Kuster, will contribute to Momentum's Scientific Advisory Board, enriching the combined team with their extensive expertise. Wilhelm commented on this collaboration, "It’s a privilege to advise this exceptional group as they continue to enhance and expand their services, providing clients with invaluable insights derived from high-quality mass spectrometry data." Kuster echoed these sentiments, noting, "The potential impact of proteomics on drug discovery is only beginning to be realized. We look forward to accelerating these advancements together."

About Momentum Biotechnologies

Momentum Biotechnologies is dedicated to serving as a drug discovery partner that empowers clients through advanced mass spectrometry technologies. The organization offers various services that include affinity-selection mass spectrometry (ASMS), covalent binding assays, and chemoproteomics, all aimed at identifying and characterizing therapeutic leads efficiently. Their state-of-the-art facilities and proven methodologies position them to deliver reliable results that tackle pressing research challenges.

For more information, visit www.momentum.bio.

About OmicScouts

OmicScouts specializes in proteomics that aids drug and biomarker discovery. Their innovative technologies and comprehensive assays monitor protein activity and function, facilitating the identification of drug targets and biomarkers of therapy response. OmicScouts’ established collaborations with leading pharmaceutical and biotechnology companies position them as trusted leaders in the field.

To learn more, please visit www.omicscouts.com.